Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team
Regulatory press release

Coegin Pharma AB: BioStock: Coegin Pharma takes advantage of decentralised clinical trials

Coegin Pharma
Read the release

Traditional clinical trials can be lengthy and are often a burden for patients involved. Patient recruitment is a major contributor to study delays and, thus, dragged-out drug development timelines. In response, we are seeing the rise of decentralised clinical trials (DCTs) - clinical trials that offer effective digital patient recruitment through digitalisation and a smooth journey for the patients throughout the study period. Coegin Pharma is a prime example of a pharma company taking advantage of DCTs through its collaboration with Studies&Me, an innovative virtual contract research organisation (CRO) based in Denmark. BioStock takes a closer look.

Read the full interview with CEO of Studie&Me, John Zibert and CEO of Coegin Pharma, Tore Duvold at biostock.se:

https://www.biostock.se/en/coegin-pharma-takes-advantage-of-decentralised-clinical-trials/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.